QGEN Investors Have Opportunity to Join Qiagen N.V. Fraud Investigation with the Schall Law Firm

QGEN Investors Have Opportunity to Join Qiagen N.V. Fraud Investigation with the Schall Law Firm LOS ANGELES, May 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Qiagen N.V. (“Qiagen” or “the Company”) (NYSE: QGEN) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Qiagen claimed in its February 5, 2026, earnings call, that QuantiFERON would accelerate to achieve “between 6% and 7% growth" in 2026. The Company presented very different guidance on April 28, 2026, when its CFO revealed that sales were projected to "continue at a largely unchanged level from the second quarter of '25," and that QuantiFERON would "return… to a more normalized growth rate in '27."

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.

310-301-3335

info@schallfirm.com